Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $15.57
Previous CloseN/A
Volume45.37K
Average Volume (3M)181.34K
Market Cap
$198.33M
Enterprise Value$91.54M
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Aug 06, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume146,821
30 Day Avg. Volume181,341
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue51.57
Enterprise Value/Gross Profit-8.31
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$32.20Price Target Upside357.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4
Revenue Forecast (FY)$512.86K
Bulls Say, Bears Say
Bulls Say
RNA‑engineered Cell Therapy PlatformCartesian’s mRNA-based ex vivo reprogramming is a durable competitive asset: it enables targeted immunomodulation without permanent genetic edits, allowing potential repeat dosing and lower long‑term safety risk versus gene‑editing approaches, supporting partnerships and platform scalability.
Focused Autoimmune Therapy PipelineConcentrating on autoimmune indications like myasthenia gravis aligns the company with large, chronic unmet medical needs. A focused clinical program increases relevance to specialist prescribers and payers, and successful proof‑of‑concept could create durable franchise value and licensing or partnership opportunities.
Substantial Assets And Low Absolute DebtDespite losses, sizable reported assets and modest formal debt provide structural flexibility: assets can support ongoing R&D and enable various financing or strategic options, while low contractual interest burden reduces near‑term solvency pressure versus highly leveraged peers.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow of this magnitude signals ongoing reliance on external capital. Over months the need for financing elevates dilution and execution risk, constraining R&D prioritization and potentially forcing unfavorable funding terms that harm long‑term strategic flexibility.
Declining Revenue And Negative EquitySharply falling revenue and large cumulative losses (negative equity) undermine internal funding capacity and indicate weak commercial traction. This structural weakness increases probability of future dilution or recapitalization, limiting ability to self‑fund clinical programs and pursue long‑term growth independently.
Loss Of Experienced Scientific Board MemberDeparture of a science committee chair reduces institutional scientific oversight and board technical depth. Even with an orderly transition, loss of this expertise can slow strategic decision‑making on clinical design or translational priorities, affecting long‑term program execution and external credibility with partners.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $15.57 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $198.33M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 73 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 29,381,514 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (357.39% Upside)
$32.20 (357.39% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.18%
12-Months-Change
Fundamentals
Return on Equity
194.13%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$32.20
▲(357.39% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.17% Insiders
7.25% Mutual Funds
3.32% Other Institutional Investors
42.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---